

Die Immuntherapie – der Leuchtturm in der Krebsbehandlung?

1. Sharma and Allison et. al, Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, Cell 161, April 9, 2015
2. Whiteside et. al, Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res; 22(8) April 15, 2016
3. Larkin J et. al, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Sep 24;373(13)
4. Keldermann and Schumacher et. al, Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. Cancer Cell 28, July 13, 2015
5. Lokhorst et. al, Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13)
6. Lonial et. al, Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7)
7. Naymagon et. al, Novel agents in the treatment of multiple myeloma: a review about the future. Journal of Hematology & Oncology (2016) 9:52
8. Müller and Kreuzaler et. al, Trastuzumab emtansine (T-DM1) renders HER2+breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine 25 Nov 2015
9. Ebert et. al, MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity 44, 609–621, March 15, 2016